Intrinsiqq
Gilead Sciences Inc. logo

Gilead Sciences Inc. Insider Trading

GILD

⊜ Compare
Last 12 months

Insiders sold $92M and bought nothing on the open market.

99% of the selling was scheduled in advance under 10b5-1 plans. Director Jeffrey Bluestone sold 625K on Nov 28, 2025, 36% of their stake, outside a plan. The last open-market buy by an executive or director was in Feb 2015.

Net open-market
−$92M
0 buys · 44 sales
Under a 10b5-1 plan
99%
of the value sold
Insiders who bought / sold
0 / 7
executives and directors
Last open-market buy
Feb 2015
Feb 6, 2015

Get an email when GILD's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Oct 30 – Nov 210b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 30,881 at avg $172.57
    $5.33M
    5.3% of stake
  • Oct 1510b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $156.22
    469K
    1.8% of stake
  • Oct 1510b5-1 plan
    Johanna Mercier
    Chief Comm & Corp Aff Officer · sold 3,000 at $156.22
    469K
    2.6% of stake
  • Oct 110b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 15,000 at avg $147.90
    $2.22M
    2.6% of stake
  • Sep 1510b5-1 plan
    Johanna Mercier
    Chief Comm & Corp Aff Officer · sold 3,000 at avg $144.22
    433K
    2.5% of stake
  • Sep 1510b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $145.29
    436K
    1.8% of stake
  • Sep 110b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 15,000 at avg $148.64
    $2.23M
    2.5% of stake
  • Aug 2610b5-1 plan
    Anthony Welters
    Director · sold 18,000 at avg $148.62
    $2.68M
    58% of stake
  • Aug 2010b5-1 plan
    Jeffrey Bluestone
    Director · sold 5,000 at avg $145.01
    725K
    33% of stake
  • Aug 1710b5-1 plan
    Johanna Mercier
    Chief Comm & Corp Aff Officer · sold 28,000 at avg $137.64
    $3.85M
    19% of stake
  • Aug 1710b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $138.36
    415K
    1.8% of stake
  • Aug 310b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 15,000 at avg $130.31
    $1.95M
    2.5% of stake
  • Jul 1510b5-1 plan
    Johanna Mercier
    Chief Comm & Corp Aff Officer · sold 3,000 at $129.92
    390K
    2.4% of stake
  • Jul 1510b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $129.93
    390K
    1.7% of stake
  • Jul 110b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 15,000 at avg $126.29
    $1.89M
    2.4% of stake
  • Jun 1510b5-1 plan
    Johanna Mercier
    Chief Comm & Corp Aff Officer · sold 3,000 at avg $123.92
    372K
    2.4% of stake
  • Jun 1510b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $125.40
    376K
    1.7% of stake
  • Jun 110b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 15,000 at avg $131.46
    $1.97M
    2.4% of stake
  • May 1510b5-1 plan
    Johanna Mercier
    Chief Comm & Corp Aff Officer · sold 28,000 at avg $131.29
    $3.68M
    18% of stake
  • May 1510b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $132.27
    397K
    1.7% of stake
  • Apr 2810b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 10,000 at avg $129.16
    $1.29M
    1.6% of stake
  • Apr 1510b5-1 plan
    Johanna Mercier
    Chief Comm & Corp Aff Officer · sold 3,000 at $140.96
    423K
    2.3% of stake
  • Apr 1510b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $140.96
    423K
    1.7% of stake
  • Mar 2710b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 10,000 at $136.82
    $1.37M
    1.5% of stake
  • Mar 1610b5-1 plan
    Johanna Mercier
    Chief Comm & Corp Aff Officer · sold 3,000 at $144.23
    433K
    2.2% of stake
  • Mar 1610b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $144.23
    433K
    1.6% of stake
  • Feb 2710b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 10,000 at avg $144.79
    $1.45M
    1.5% of stake
  • Feb 1710b5-1 plan
    Johanna Mercier
    Chief Comm & Corp Aff Officer · sold 28,000 at avg $154.44
    $4.32M
    19% of stake
  • Feb 1710b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $154.43
    463K
    1.8% of stake
  • Feb 510b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 115,640 at $150.00
    $17.3M
    16% of stake
  • Jan 2810b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 10,000 at avg $139.89
    $1.4M
    1.8% of stake
  • Jan 2310b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 115,640 at $135.00
    $15.6M
    17% of stake
  • Jan 2010b5-1 plan
    Jeffrey Bluestone
    Director · sold 5,000 at $123.50
    618K
    36% of stake
  • Jan 1510b5-1 plan
    Johanna Mercier
    Chief Commercial Officer · sold 3,000 at $124.31
    373K
    2.8% of stake
  • Jan 1510b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $124.31
    373K
    2.0% of stake
  • Dec 29, 202510b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 10,000 at $124.83
    $1.25M
    1.7% of stake
  • Dec 15, 202510b5-1 plan
    Johanna Mercier
    Chief Commercial Officer · sold 3,000 at $122.00
    366K
    2.7% of stake
  • Dec 15, 202510b5-1 plan
    Andrew D Dickinson
    Chief Financial Officer · sold 3,000 at $122.00
    366K
    1.9% of stake
  • Nov 28, 2025No plan
    Jeffrey Bluestone
    Director · sold 5,000 at $125.08
    625K
    36% of stake
  • Nov 28, 202510b5-1 plan
    Daniel Patrick O'Day
    Chairman & CEO · sold 10,000 at avg $126.54
    $1.27M
    1.7% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch GILD, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with GILD

CompareIntrinsic value
AMGNAmgen Inc.
$478.48+3.73%45
BIIBBiogen Inc.
$254.46+2.22%39
NBIXNeurocrine Biosciences Inc.
$167.21+1.43%85
UPCUniverse Pharmaceuticals Inc.
$1.47-1.34%39
TEVATeva Pharmaceutical Industries Ltd
$42.13+0.52%46
ABTAbbott Laboratories
$115.55+5.62%25
REGNRegeneron Pharmaceuticals, Inc.
$930.67-4.39%54
VTRSViatris Inc.
$19.22+1.59%24

Held by ETFs

GILD is in 462 US ETFs. The largest of them, with GILD's weight in each:

Spot a number that looks wrong? Check it in GILD's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GILD

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.